title: Exemestane in the prevention setting.
abstract: Aromatase inhibitors are well-established therapies in the neoadjuvant, adjuvant and metastatic settings for breast cancer. In adjuvant trials, this class of drugs has shown preventative properties by decreasing the rate of contralateral breast cancer. Recently, the National Cancer Institute of Canada Clinical Trials Group MAP.3 study evaluated exemestane as a breast cancer prevention agent for women with specified higher risks of developing breast cancer. We review the history of exemestane and evaluate the available evidence of its use for breast cancer prevention.
authors.affiliation: Department of Breast Medical Oncology, The University of Texas MD Anderson Cancer Center, 1515 Holcombe Boulevard, Unit 1354, Houston, TX 77030, USA.
authors.forename: Jennifer Keating
authors.initials: JK
authors.lastname: Litton
authors.forename: Therese B
authors.initials: TB
authors.lastname: Bevers
authors.forename: Banu K
authors.initials: BK
authors.lastname: Arun